Detail akcie Kuros Bioscienc N online

Business Summary: Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Kuros Biosciences AG revenues increased 87% to SF33.6M. Net loss decreased 6% to SF13.7M. Revenues reflect Revenue from product sales increase from SF13.3M to SF33.6M. Lower net loss reflects Finance income increase from SF1.8M to SF3.8M (income), GENERAL COST decrease of 70% to SF766K (expense), Finance costs - Balancing value decrease of 9% to SF3.9M (expense).